tDCS for Cognitive Impairment After Stroke
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a treatment called transcranial direct current stimulation (tDCS) to determine its effectiveness in improving brain function and memory for individuals with cognitive issues after a stroke. Participants will receive either active tDCS or a placebo version to compare effects. Individuals who have experienced an ischemic stroke (caused by a blocked blood vessel) within the last five months and are facing memory or thinking problems may qualify to join. As a Phase 2 trial, this research measures the treatment's effectiveness in an initial, smaller group, allowing participants to contribute to important early-stage findings.
Do I need to stop my current medications for the trial?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What prior data suggests that this technique is safe for treating cognitive impairment after stroke?
Research has shown that transcranial direct current stimulation (tDCS) is generally safe. In studies, only about 11.62% of reports mentioned any side effects in stroke patients using tDCS. The most common issues were mild, such as itching (70%) and a burning sensation. Importantly, trials using standard tDCS methods, which typically involve short sessions with low electrical current, have reported no serious side effects. This suggests that participants tolerate tDCS well.12345
Why do researchers think this study treatment might be promising for cognitive impairment after stroke?
Researchers are excited about using transcranial direct current stimulation (tDCS) for cognitive impairment after a stroke because it offers a unique and non-invasive approach to treatment. Unlike traditional therapies like medication or physical rehabilitation, tDCS uses a low electrical current applied to the scalp to stimulate brain activity, potentially enhancing cognitive recovery. This method might provide a quicker and more targeted way to improve brain function, which could lead to faster and more effective rehabilitation outcomes for stroke survivors.
What evidence suggests that tDCS is effective for cognitive impairment after stroke?
Research has shown that transcranial direct current stimulation (tDCS) can improve thinking and memory in individuals struggling with these skills after a stroke. In this trial, participants will receive either active tDCS or sham (placebo) tDCS. One study demonstrated that using tDCS on the left side of the brain enhanced patients' ability to remember sounds. Another study found that combining tDCS with mental exercises significantly improved overall thinking skills and the ability to manage daily tasks. Additionally, using tDCS at home proved to be a safe and effective method for addressing memory and thinking problems post-stroke. These findings suggest that tDCS could be a promising support for stroke survivors facing these challenges.56789
Are You a Good Fit for This Trial?
This trial is for individuals who have experienced a stroke and are now dealing with cognitive impairments, specifically issues with memory. The details of the inclusion and exclusion criteria were not provided.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive active or sham tDCS for 20 minutes, for 10 sessions
Follow-up
Participants are monitored for changes in cognitive function, blood markers, and brain activity
What Are the Treatments Tested in This Trial?
Interventions
- Transcranial Direct Current Stimulation
Transcranial Direct Current Stimulation is already approved in United States, European Union for the following indications:
- Chronic pain management
- Depression
- Anxiety
- Chronic pain management
- Neurological rehabilitation
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Oklahoma
Lead Sponsor
American Heart Association
Collaborator